Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04025879 · ClinicalTrials.gov registry record · Phase 3

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

A Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Bristol-Myers Squibb.

Active
Registry status
Phase 3
Development phase
461
Enrollment target
20
Study locations

NCT04025879 is a Phase 3 study of Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 461 participants, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (44% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04025879, a Phase 3 study of Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
461 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG Carboplatin
  • DRUG Cisplatin
  • DRUG Pemetrexed
  • DRUG Paclitaxel
  • BIOLOGICAL Nivolumab

Study Locations (20)

Illinois

  • Local Institution - 0145 - Chicago
  • Local Institution - 0078 - Chicago
  • Local Institution - 0121 - Orland Park

Georgia

  • Local Institution - 0040 - Atlanta
  • Local Institution - 0120 - Augusta

Massachusetts

  • Local Institution - 0076 - Boston
  • Local Institution - 0074 - Newton

Ohio

  • Local Institution - 0055 - Cincinnati
  • Local Institution - 0102 - Cleveland

Other

  • Local Institution - 0043 - Buenos Aires
  • Local Institution - 0030 - CABA

Florida

  • Local Institution - 0104 - Tampa

Maryland

  • Rcca Md Llc - Bethesda

Michigan

  • Local Institution - 0086 - Traverse City

Trial Details

FieldValue
Enrollment Target 461 participants
Start Date 2019-11-05
Est. Completion 2027-07-30
Phase Phase 3

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04025879

The ClinicalTrials.gov registry entry for NCT04025879 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 461 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (44% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT04025879 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Illinois, Georgia, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04025879 about?

NCT04025879 is a clinical study titled "A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer". The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.

What is the current status of trial NCT04025879?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 461 participants. The study started on 2019-11-05. Estimated completion is 2027-07-30.

What conditions does trial NCT04025879 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT04025879?

The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), Nivolumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT04025879?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04025879 being conducted?

This trial has 20 study locations across Florida, Georgia, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.